New Drugs of ,3,5,7,10,14,16,20,22,24,26,28,30,32,34,36,38,40,41,43,45-86 Brand Name/ Generic Name/ Approved Indication
|
|
- Gillian Hoover
- 5 years ago
- Views:
Transcription
1 1 New Drugs of ,3,5,7,10,14,16,20,22,24,26,28,30,32,34,36,38,40,41,43,45-86 Brand Name/ Generic Name/ Approved Indication Company Aliqopa Copanlisib Dihydrochloride Intravenous Bayer HealthCare Pharmaceuticals Inc. Alunbrig Brigatinib Tablets ARIAD Pharmaceuticals, Inc. Austedo Deutetrabenazine Tablets Teva Pharmaceuticals USA, Inc. Bavencio Avelumab Intravenous EMD Serono, Inc. Baxdela Delafloxacin Meglumine Tablets and Intravenous Melinta Therapeutics, Inc. Treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of chorea associated with Huntington s disease Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy Treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of gram-positive and negative organisms Benznidazole Benznidazole Tablets Exeltis USA, Inc Besponsa Inotuzumab Ozogamicin Intravenous Wyeth Pharmaceuticals, Inc Brineura Cerliponase Alfa Intraventricular BioMarin Pharmaceutical Inc Bevyxxa Betrixaban Capsules Portola Pharmaceuticals, Inc. Calquence Acalabrutinib Capsules Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) Indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency Prophylaxis of venous thromboembolism in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
2 2 AstraZeneca Pharmaceuticals LP Cyltezo Adalimumab-adbm Subcutaneous Boehringer Ingelheim Pharmaceuticals, Inc. Dupixent Dupilumab Subcutaneous Regeneron Pharmaceuticals, Inc. Emflaza Deflazacort Tablets and Oral Suspension Marathon Pharmaceuticals, LLC Fasenra Benralizumab Subcutaneous AstraZeneca Pharmaceuticals LP Giapreza Angiotensin II Intravenous Infusion La Jolla Pharmaceutical Company Haegarda C1 Esterase Inhibitor [Human] Subcutaneous CSL Behring LLC Hemlibra Emicizumab-kxwh Subcutaneous Genentech, Inc Heplisav-B Hepatitis B Vaccine (Recombinant), Adjuvanted Solution for Intramuscular Dynavax Technologies Idhifa Enasidenib Mesylate Tablets Celgene Treatment of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Adult Crohn s Disease, Ulcerative Colitis, and Plaque Psoriasis Treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Treatment of Duchenne muscular dystrophy in patients 5 years of age and older Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype Vasoconstrictor to increase blood pressure in adults with septic or other distributive shock Routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors Prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDAapproved test
3 3 Imfinzi Durvalumab Intravenous AstraZeneca Pharmaceuticals LP Ingrezza Valbenazine Tosylate Capsules Neurocrine Biosciences, Inc. Ixifi Infliximab-qbtx Intravenous Pfizer, Inc. Kedrab Rabies Immune Globulin Intramuscular Kedrion Biopharma Inc. Kevzara Sarilumab Subcutaneous Sanofi-Aventis U.S. LLC Kisqali Ribociclib Succinate Tablets Novartis Pharmaceuticals Kymriah Tisagenlecleucel Novartis Pharmaceuticals Macrilen Macimorelin Oral Solution Aeterna Zentaris Mavyret Glecaprevir and Pibrentasvir Tablets AbbVie, Inc Mepsevii Vestronidase-Alfa-vjbk intravenous Ultragenyx Pharmaceutical Inc. Mvasi Bevacizumab-awwb Intravenous Solution Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Treatment of tardive dyskinesia. Treatment of Crohn s Disease, Pediatric Crohn s Disease, Ulcerative Colitis, Rheumatoid Arthritis in combination with methotrexate, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis Passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs Indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse Indicated for the diagnosis of adult growth hormone deficiency Treatment of patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis as well as patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. Treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome) in pediatric and adult patients Metastatic colorectal cancer, Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Glioblastoma, Metastatic renal cell carcinoma, and Cervical cancer
4 4 Amgen Inc. Nerlynx Neratinib Maleate Tablets Puma Biotechnology, Inc. Ocrevus Ocrelizumab Intravenous Genentech, Inc. Odactra House Dust Mite Allergen Extract Sublingual Tablets. Ogivri Trastuzumab-dkst Intravenous Mylan Ozempic Semaglutide Subcutaneous Novo Nordisk Inc. Parsabiv Etelcalcetide Intravenous KAI Pharmaceuticals, Inc. Prevymis Letermovir Tablets and. Radicava Edaravone Intravenous MT Pharma America, Inc. Rebinyn Factor IX, GlycoPEGylated Intravenous Novo Nordisk Inc. Renflexis Infliximab-adba Intravenous Rhopressa Netarsudil ophthalmic solution Aerie Pharmaceuticals, Inc Indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy Treatment of patients with relapsing or primary progressive forms of multiple sclerosis Indicated as immunotherapy for house dust mite (HDM)- induced allergic rhinitis, with or without conjunctivitis in adults 18 through 65 years of age Treatment of HER2-overexpressing breast cancer and treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in adults with type 2 diabetes mellitus Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). Treatment of amyotrophic lateral sclerosis (ALS) Indicated for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes or perioperative management of bleeding Treatment of Crohn s Disease, Pediatric Crohn s Disease, Ulcerative Colitis, Rheumatoid Arthritis in combination with methotrexate, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis Indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
5 5 Rituxan Hycela Rituximab / Hyaluronidase Human Subcutaneous Genentech, Inc Rydapt Midostaurin Capsules Novartis Pharmaceuticals Segluromet Ertugliflozin / Metformin Hydrochloride Tablets Shingrix Zoster Vaccine Recombinant, Adjuvanted Intramuscular GlaxoSmithKline Siliq Brodalumab Subcutaneous Valeant Pharmaceuticals North America LLC Solosec Secnidazole Oral Granules Symbiomix Therapeutics LLC Steglatro Ertugliflozin Tablets Steglujan Ertugliflozin / Sitagliptin Tablets Symproic Naldemedine Tosylate Tablets Shionogi Inc. Tremfya Guselkumab Subcutaneous Janssen Biotech, Inc Trulance Plecanatide Tablets Synergy Pharmaceuticals Inc. Treatment of adult patients with Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Chronic Lymphocytic Leukemia (CLL) Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. Prevention of herpes zoster (shingles) in adults aged 50 years and older. Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Treatment of bacterial vaginosis in adult women. in adults with type 2 diabetes mellitus in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. Treatment of opioid-induced constipation Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Treatment of chronic idiopathic constipation
6 6 Tymlos Abaloparatide Subcutaneous Radius Health, Inc. Vabomere Meropenem and Vaborbactam Intravenous Verzenio Abemaciclib Tablets Lilly USA, LLC Vosevi Sofosbuvir, Velpatasvir, and Voxilaprevir tablets Gilead Sciences, Inc. Vyzulta Latanoprostene Bunod Ophthalmic Solution Bausch & Lomb Xadago Safinamide Mesylate Tablets US WorldMeds, LLC Xepi Ozenoxacin Cream Medimetriks Pharmaceuticals, Inc Xermelo Telotristat Etiprate Tablets Lexicon Pharmaceuticals, Inc. Yescarta Axicabtagene Ciloleucel Intravenous Kite Pharma, Inc Zejula Niraparib Tosylate Capsules Tesaro, Inc. Treatment of postmenopausal women with osteoporosis at high risk for fracture. Treatment of complicated urinary tract infections including pyelonephritis. In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and as monotherapy for the treatment of adult patients with HR positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting Treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child- Pugh A) who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Reduction of intraocular pressure in patients with openangle glaucoma or ocular hypertension Adjunctive treatment to levodopa/carbidopa in patients with Parkinson s disease experiencing off episodes Topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Clinical Overview of Innovative New Drug Approvals in 2017
Reddy: Clinical Overview of Innovative New Drug Approvals in 2017 4225 International Journal of Pharmaceutical Sciences and Nanotechnology Review Article Clinical Overview of Innovative New Drug Approvals
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE THIRD QUARTER 2017 NEW DRUG ARRIVALS SUMMARY TABLE. Utilization Management Recommendation
RT 1,2, 3,5 Drug Name 1 Brigatinib (Alunbrig ) 1 Deutetrabenazine (Austedo ) 1 Cerliponase alfa (Brineura ) Review Reason FDA-Approved (s) Alunbrig is indicated patients with anaplastic lymphoma kinase
More informationFDA Approval LIST. WellINFORMED. Generic Name(s) Brand Name (manufacturer) Therapeutic Use. Brief Description. Potential Impact.
FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated
More informationCover story. Austedo Ingrezza Brineura Alunbrig Rydapt Tymlos Imfinzi Radicava Kevzara Baxdela Bevyxxa
Cover story Downloaded via 148.251.232.83 on March 9, 2019 at 14:34:33 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. Trulance Parsabiv Emflaza
More informationLUNCH AND LEARN. May 11, CE Activity Information & Accreditation
LUNCH AND LEARN May 11, 2018 Featured Speaker: Mary Lynn Moody, B.S. Pharm. Assistant Dean for Business Development Clinical Associate Professor Drug Information and Prior Authorization Group Department
More informationAdded, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationWell Informed. Utilization Program Updates to Promote Guideline Adherence. Effective January 1, 2018:
Q3 2 0 1 7 As we continue our rapid growth under the ownership of The Carlyle Group, we have a lot of exciting news to share. This edition details upcoming changes to our 2018 drug utilization programs
More informationLUNCH AND LEARN. April 13, CE Activity Information & Accreditation
LUNCH AND LEARN New Drugs of 2017: Part 1 April 13, 2018 Featured Speaker: Mary Lynn Moody, B.S. Pharm. Assistant Dean for Business Development Clinical Associate Professor Drug Information and Prior Authorization
More informationWell Informed. WellManaged - Diabetes INTRODUCING: WellDyneRx plan participants are eligible to receive a free One Touch System glucose meter
Q4 2 0 1 7 Well Informed With 2017 winding down, we re taking stock of how we performed throughout the year and setting goals for 2018. Towards that end, we recently distributed our annual Client Satisfaction
More informationLaurajo Ryan, PharmD, MSc, BCPS Clinical Associate Professor
NEW DRUG UPDATE 2018 Laurajo Ryan, PharmD, MSc, BCPS Clinical Associate Professor RyanL@uthscsa.edu Bryson Duhon, PharmD, BCPS Clinical Assistant Professor Duhon@austin.utexas.edu Accreditation New Drug
More informationMedicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationMarch 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationNEW DRUG UPDATE. Financial Disclosures. FDA Approvals. Objectives. Withdrawals. Mark S. Johnson, Pharm.D., BCPS
Financial Disclosures NEW DRUG UPDATE Mark S. Johnson, Pharm.D., BCPS Name of commercial interest(s) Stockholder in Merck and various mutual funds Mark S. Johnson, Pharm.D., BCPS Professor of Pharmacy
More informationSpecialty Pipeline Monthly Update
Specialty Pipeline Monthly Update Critical updates in an ever changing environment September 2017 New drug information Gocovri (amantadine HCl XR): The U.S. Food and Drug Administration (FDA) approved
More informationNew Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More informationAdded, Removed or Changed. Added, Removed or Changed
One mission: you s March 8, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationPharmacology Update. Power. Note one action you ll take after attending this session:
Pharmacology Update Sunday, May 20 8 9:30 am Note one action you ll take after attending this session: Teresa Knoop, MSN, RN, AOCN Vanderbilt Ingram Cancer Center Assistant Director Clinical Operations
More informationCancer Therapy Update in 2017
Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory
More informationKentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationJanuary 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationNew Drug Update: 2018
New Drug Update: 2018 Wesley Lindsey, Pharm.D. Associate Clinical Professor Auburn University Harrison School of Pharmacy Drug Information and Learning Resource Center Bio Undergraduate: University of
More informationManufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 31.05.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
More informationOral Oncology Agents. August 2017 Update. SGLT-2 Category Update. Removal of Medical Foods
SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE SEPTEMBER 2017 ISSUE 4 HELPFUL NUMBERS FOR PROVIDERS CVS: 1-888-512-8935 Primary: 004336 Secondary Commercial: 013089 Secondary
More informationDirectorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
More informationA MONTHLY DOSE OF EDUCATION
A MONTHLY DOSE OF EDUCATION Brian Pelletier, PharmD, BCGP, FASCP CEO, A Dose of Education, LLC December 2017 FDA Approval Ozempic (semaglutide) approved 12/5/17 A glucagon-like peptide 1 (GLP-1) receptor
More informationSpecialty Pharmacy Pipeline
Specialty Pharmacy Pipeline Drugs to Watch Anticipated Launches Q1 Q2 2017 Atopic Dermatitis Dupixent (dupilumab) Subcutaneous injection Regeneron Pharmaceuticals/Sanofi moderate-to-severe atopic dermatitis
More informationKentucky Department for Medicaid Services Drug Review and Options for Consideration
The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the November 16, 2017 meeting of the Pharmacy and Therapeutics Advisory Committee. Maximum Duration
More informationSpecialty Pipeline Monthly Update
Specialty Pipeline Monthly Update Critical updates in an ever changing environment June 2017 New drug information Kevzara (sarilumab): Sanofi/Regeneron Pharmaceuticals received Food and Drug Administration
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More informationNew Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications
Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced
More informationList of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013
S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > March New drug information Xermelo (telotristat etiprate): The U.S. Food and Drug Administration (FDA) granted approval of Lexicon s Xermelo tablets for the
More informationDisclosures. Dr. Burton and Dr. Podoloff have no actual or potential conflict of interest associated with this presentation
New Drug Update 2018 Aaron Burton, PharmD, BCPS Assistant Professor University of Saint Joseph School of Pharmacy Jennifer Podoloff, PharmD, BCPPS Assistant Professor University of Saint Joseph School
More informationNew Drug Update 2018 Aaron Burton, PharmD, BCPS Assistant Professor University of Saint Joseph School of Pharmacy. Cardiology 3/1/2018
Disclosures Dr. Burton and Dr. Podoloff have no actual or potential conflict of interest associated with this presentation New Drug Update 2018 Aaron Burton, PharmD, BCPS Assistant Professor University
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationDescription of Commitment
AbbVie U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / 022309 and 021015 20725 20725 125057/0 125057/114 Description of A randomized, double-blind,
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationWashington October Newsletter
Washington October Newsletter October 19, 2017 CMS Education on Medicare Skilled Nursing and Therapy Services Coverage The Centers for Medicare and Medicaid (CMS) want to remind you that the Jimmo v. Sebelius
More informationNew Mexico Health Connections Drug Safety Updates Q4 2018
Dupixent dupilumab Moderate-to-severe atopic dermatitis, Moderate-to-Severe asthma SQ Injection On October 19, 2018, new warnings were added to the Dupixent drug label regarding judicious use in eosinophilic
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationFDA Approval LIST. WellINFORMED
FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated
More informationCortellis Drugs to Watch 2017
Cortellis Drugs to Watch 2017 The 2017 edition of the annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$1 billion by 2021, as
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More information6/29/2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018
Disclosure Statement New Drugs I have no conflicts of interest to disclose Steven Walden, PharmD, MPH WellCare Health Plans Manager, Clinical Implementations Learning Objectives At the completion of this
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationPfizer Pipeline. August 9, 2012
Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationintolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*
What s New Medical Pharmaceutical Policy March 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated policy Remicade (infliximab), Inflectra (infliximab-dyyb)
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationManufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 04.07.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More informationFebruary - March - April 2017 Selected Content Updates. Approved to treat chorea associated with Huntington disease
Selected Content for Customer Newsletter and Content Link February March April 2017 FDA Approvals new monographs and patient medication instructions Abaloparatide (Tymlos ) Approved to reduce the risk
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More information3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More informationContents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.
May 2018 In This Issue Coverage Guidelines Revised for Azacitidine (Vidaza)... 3 Coverage Guidelines Revised for Fulvestrant (Faslodex)... 4 Place of Service Revised for Total Hip and Total Knee Arthroplasty...
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationNew therapeutic agents marketed in 2017: Part 3
New therapeutic agents marketed in 2017: Part 3 Introduction Part 1 (Pharmacy Today, September 2017) of this three-part series on new FDAapproved therapeutic agents marketed in 2017 reviewed seven new
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationPfizer Pipeline. November 8, 2012
Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationFDA Corner. Molecular and Cellular Pharmacology
FDA Corner FDA Approves Drug to Treat Duchenne Muscular Dystrophy approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD),
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationNICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationNICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017
NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within
More informationNCCN Guidelines for B-Cell Lymphomas V Update Meeting 08/14/18
DIAG-1 Submission request from Adaptive Biotechnologies to add NGS as an additional option to PCR for assessing IGH and TCR gene rearrangements under Essential Diagnosis: (immunohistochemistry, flow cytometry,
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationNew Drugs Update: Targeted Therapies
NEW DRUG UPDATES New Drugs Update: Targeted Therapies Megan Derba, Pharm.D. Supervising Pharmacist Hematology/Oncology Lafayette Family Cancer Institute Brewer, Maine November 2, 2018 Introduction Disclosures
More informationMedicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationBarbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
More informationR&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018.
R&D Pipeline (As of Apr 2018) Underlined items indicate changes from the previous announcement on Jan 31, 2018. Oncology (1/2) MDV3100 enzalutamide Androgen receptor inhibitor Castration-resistant prostate
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationCompassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationAnticipated Launches Q Q1 2019
Anticipated Launches Q4 2018-Q1 2019 Disease Prevalence Amyloidosis Tegsedi (inotersen) subcutaneous (SC) injection Akcea s/ionis Pharmaceuticals hereditary transthyretin amyloidosis (hattr) with polyneuropathy,
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationNEW FDA DRUG APPROVALS
NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationPharmacotherapy Update 2017: General Health
Pharmacotherapy Update 2017: General Health B. Andrew Mardis, PharmD, BCPS 24 rd Annual Charleston APRN Conference Charleston, South Carolina February 21, 2018 Disclaimer I have no conflicts of interest
More information